99 results
8-K
EX-99.1
IVVD
Invivyd Inc
9 May 24
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
4:08pm
previously authorized for EUA. There are limitations of the data supporting the benefits of PEMGARDA. Evidence of clinical efficacy for other
8-K
EX-99.1
IVVD
Invivyd Inc
7 May 24
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19
7:38am
, the parent mAb of pemivibart, and other mAbs that were previously authorized for EUA. There are limitations of the data supporting the benefits … and accelerate product availability; the potential benefits of a new COVID-19 treatment mAb, if authorized or approved, to certain vulnerable
8-K
EX-99.1
IVVD
Invivyd Inc
12 Apr 24
Invivyd Announces CEO Transition
7:36am
, the parent mAb of pemivibart, and other mAbs that were previously authorized for EUA. There are limitations of the data supporting the benefits of PEMGARDA … statements concerning, among other things, the anticipated benefits of the company’s management transition; the company’s anticipated next phase
8-K
EX-10.1
yhzypzrxnh2y222ov5p6
12 Apr 24
Invivyd Announces CEO Transition
7:36am
8-K
EX-99.1
7th5av
4 Apr 24
Invivyd Provides PEMGARDATM Launch Update and Announces 2024 Net Product
5:25pm
8-K
EX-99.1
jc77gx 3ng
28 Mar 24
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
7:05am
8-K
EX-99.1
7gmwe4 84ia2uojmnx
22 Mar 24
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
8:58pm
8-K
EX-99.3
3u2m5spjhzn54
22 Mar 24
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
8:58pm